secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2026-09-03T15:45:15+00:00
Accession:  0001493152-26-041333
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma effects 1-for-25 reverse stock split, cuts authorized shares to 26.5M
--------------------------------------------------------------------------------

- Reverse split effective 12:01 a.m. ET Sept 8, 2026; trading on split-adjusted basis begins at market open.
- Outstanding shares drop from ~45,109,497 to ~1,804,379; no fractional shares, cash paid for fractions.
- Authorized capital reduced from 265M to 26.5M shares (25M common, 1.5M preferred); new CUSIP 36254L407.
- Certificates of Elimination filed for Series A-K preferred; all Series C converted, no other preferred outstanding.
- Board approved 1-for-25 ratio on Aug 27, 2026, following stockholder authorization at Aug 14 meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315226041333/0001493152-26-041333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315226041333/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-041333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer